ArticleScientific reports2026
Identification and verification of biomarkers associated with integrated stress response in heart failure.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Heart failure (HF) is a global disease affecting millions worldwide. This study aimed to identify and validate HF biomarkers associated with the integrated stress response (ISR), providing novel insights into pathogenesis and potential therapeutic targets. Transcriptomic datasets were acquired from open-access repositories, and integrated stress response-related genes (ISRGs) were compiled through literature review. Candidate biomarkers were identified by overlapping ISRGs with differentially expressed genes (DEGs), followed by machine learning selection and expression validation. Functional analyses included nomogram construction, enrichment analysis, immune infiltration assessment, regulatory network building, drug prediction, tissue expression profiling, and RT-qPCR validation. PSME4 and SQSTM1 were identified as key biomarkers. The nomogram model exhibited strong predictive accuracy for HF. Enrichment analyses indicated that these genes were associated with pathways such as ribosome and viral myocarditis. Eight immune cell types, including neutrophils and follicular helper T cells, were significantly altered. Regulatory analysis revealed that the biomarkers were predicted to be modulated by miRNAs (e.g., hsa-miR-7-5p) and indirectly regulated by lncRNAs (e.g., ZFAS1). Besides, several drugs, including demecolcine and bortezomib, were predicted for therapeutic potential. Tissue-specific expression analysis confirmed differential levels, and RT-qPCR revealed reduced PSME4 and elevated SQSTM1 expression in HF patients. PSME4 and SQSTM1 were identified as ISR-related biomarkers in HF, highlighting their potential for diagnostic application and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.